You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CML-CP, AP

Showing 1 - 25 of 2,480
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

3rd Line Therapy or More to Treat Adult CML- CP in Real World

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Asciminib
  • (no location specified)
Oct 16, 2023

Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Treatment-free Remission
  • TFR(Treatment-Free Remission)
  • (no location specified)
Jun 27, 2022

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Terminated
Has Results
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Jacksonville, Florida
  • +9 more
Nov 6, 2021

Among CP-CML Participants Initiating Dasatinib inReal Life

Completed
  • Chronic Myeloid Leukemia
  • Non-Interventional
  • Paris, France
    Local Institution
Jun 17, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed
  • Chronic Myeloid Leukemia
  • 3L Therapy
  • T315I
  • Lyon, France
    Novartis Investigative Site
Nov 9, 2022

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

Recruiting
  • Leukemia, Chronic Myelogenous
  • Chongqing City, Chongqing, China
  • +23 more
Jan 18, 2023

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

Withdrawal of Second-generation Tyrosine Kinase Inhibitors After

Recruiting
  • MMR on 12 Month
  • Guangzhou, Guangdong, China
  • +1 more
Apr 21, 2022

Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

Recruiting
  • Philadelphia Chromosome
  • +4 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 23, 2022

Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

Recruiting
  • Chronic Myelogenous Leukemia
  • ABL001 40mg BID
  • +2 more
  • Caba, Buenos Aires, Argentina
  • +53 more
Jan 27, 2023

CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

Recruiting
  • CML, Chronic Phase
  • CML, Accelerated Phase
  • HS-10382(Part 1: Dose escalation)
  • HS-10382(Part 2: Dose expansion)
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia Trial in Worldwide (nilotinib)

Completed
Has Results
  • Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
  • Loma Linda, California
  • +35 more
Mar 25, 2021

Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • Detroit, Michigan
  • +1 more
May 3, 2022

Chronic Myelogenous Leukemia - Chronic Phase Trial in China (Dasatinib Tablets)

Completed
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Dasatinib Tablets
  • Shenzhen, Guangdong, China
  • +3 more
Jun 11, 2021

Withdrawal or Reduction TKIs in CML-CP

Recruiting
  • MMR on 12 Month
  • withdrawal TKIs or halve TKIs
  • Guangzhou, Guangdong, China
    NanfangH
Sep 2, 2021

Chronic Myeloid Leukemia Trial in Worldwide (KRT-232, Dasatinib, Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia
  • Birmingham, Alabama
  • +25 more
Mar 4, 2022

CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

Recruiting
  • CML
  • +3 more
  • Asciminib add-on
  • +3 more
  • Augusta, Georgia
  • +46 more
Jan 23, 2023

Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
  • (no location specified)
Jun 7, 2022

CML, Imatinib Trial in Seoul (high-dose imatinib)

Completed
  • CML
  • Imatinib
  • high-dose imatinib
  • Seoul, Korea, Republic of
    Novartis Investigational Site
Mar 9, 2021

3L+ Therapies Among Chronic Myeloid Leukemia and Those With

Completed
  • Chronic Myeloid Leukemia
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 11, 2022